Pregnancy planning and management in patients with multiple endocrine neoplasia type 1


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Each case of pregnancy in patients with multiple endocrine neoplasia type 1 (MEN-1) should be followed up by an interdisciplinary team of physicians, which is a prerequisite for the effective control of outcomes for both the mother and the fetus. Publications on this topic are quite limited in foreign literature, and Russian articles have not yet been submitted. Description. The paper gives two cases of successful pregnancy management in patients with the classical phenotype of MENP-1, which was verified before conception with a favorable outcome for the mother and the baby. One of the patients was recorded during pregnancy to have progressive pancreatic tumor growth, which required subtotal resection after delivery. Conclusion. The main therapeutic goal in the planning and managing of pregnancy in patients with MEN-1 is to correctly and consistently control its associated diseases, by analyzing the risk/benefit ratio for the chosen tactics.

Full Text

Restricted Access

About the authors

N. G Mokrysheva

National Medical Research Center of Endocrinology, Ministry of Health of Russia

Yu. A Krupinova

National Medical Research Center of Endocrinology, Ministry of Health of Russia

Email: j.krupinova@gmail.com

A. K Eremkina

National Medical Research Center of Endocrinology, Ministry of Health of Russia

Email: parathyroid.enc.@gmail.com

E. A Dobreva

National Medical Research Center of Endocrinology, Ministry of Health of Russia

Email: dobrevae@mail.ru

D. V Podluzhnyi

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: dr.podluzhny@mail.ru

G. A Melnichenko

National Medical Research Center of Endocrinology, Ministry of Health of Russia

Email: teofrast2000@mail.ru

References

  1. Thakker R.V. Genetics of parathyroid tumours. J. Intern Med. 2016; 280(6): 574-83. doi: 10.1111/joim.12523
  2. GiustiF, Cianferotti L., Boaretto F., Cetani F., Cioppi F., Colao A., et al. Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. Endocrine. 2017; 58(2): 349-59. doi: 10.1007/s12020-017-1234-4
  3. Sakurai A., Suzuki S., Kosugi S., Okamoto T., Uchino S., Miya A. etal. Multiple endocrine neoplasia type 1 in Japan: establishment and analysis of a multicentre database. Clin Endocrinol (Oxf). 2012; 76(4): 533-9. doi: 10.1111/j.1365-2265.2011.04227.x
  4. Trouillas J., Labat-Moleur F., Sturm N., Kujas M., Heymann M.-F, Figarella-Branger D., et al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J. Surg Pathol. 2008; 32(4): 534-43. doi: 10.1097/PAS.0b013e31815ade45
  5. Goudet P., Murat A., Binquet C., Cardot-Bauters C., Costa A., Ruszniewski P., et al. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) cohort study among 758 patients. World J. Surg. 2010; 34(2): 249-55. doi: 10.1007/s00268-009-0290-1
  6. Ito T., Igarashi H., Uehara H., Berna M.J., Jensen R.T. Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore). 2013; 92(3): 135-81. DOI: 10.1097/ MD.0b013e3182954af1
  7. Schaaf L., Pickel J., Zinner K., Hering U., Hofler M., Goretzki P.E., et al. Developing effective screening strategies in multiple endocrine neoplasia type 1 (MEN 1) on the basis of clinical and sequencing data of German patients with MEN 1. Exp Clin Endocrinol Diabetes Off J. Ger Soc Endocrinol Ger Diabetes Assoc. 2007; 115(8): 509-17. DOI: 10.1055/ s-2007-970160
  8. Manoharan J., Raue F., Lopez C.L., Albers M.B., Bollmann C., Fendrich V., et al. Is Routine Screening of Young Asymptomatic MEN1 Patients Necessary? World J. Surg. 2017; 41(8): 2026-32. doi: 10.1007/s00268-017-3992-9
  9. Machens A., Schaaf L., Karges W., Frank-Raue K., Bartsch D.K., Rothmund M., et al. Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin Endocrinol (Oxf). 2007; 67(4): 613-22. doi: 10.1111/j.1365-2265.2007.02934.x
  10. Triponez F., Sadowski S.M., Pattou F., Cardot-Bauters C., Mirallie E., Le Bras M., et al. Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small 10.1097/SLA.0000000000002191
  11. de Laat J.M., Pieterman C.R.C., Weijmans M., Hermus A.R., Dekkers O.M., de Herder W.W., et al. Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 patients. J. Clin Endocrinol Metab. 2013; 98(10): 4143-51. DOI: 10.1210/ jc.2013-1800
  12. Daglar H.K., Kirbas A., Biberoglu E., Laleli B., Danisman N. Management of a multiple endocrine neoplasia type 1 during pregnancy: A case report and review of the literature. J. Exp Ther Oncol. 2016; 11(3): 217-20. PMID: 28471129
  13. Mistry M., Gupta M., Kaler M. Pregnancy in multiple endocrine neoplasia type 1 equals multiple complications. Obstet Med. 2014; 7(3):123-5. doi: 10.1177/1753495X14532634
  14. Thompson M., Burgess J. No evidence of adverse fertility and pregnancy outcomes in patients with unrecognized and untreated multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf). 2019; 90(2): 312-9. DOI: 10.1111/ cen.13890
  15. Malekar-Raikar S., Sinnott B.P. Primary hyperparathyroidism in pregnancy-a rare cause of life-threatening hypercalcemia: case report and literature review. Case Rep Endocrinol. 2011; 2011: 520516. doi: 10.1155/2011/520516
  16. Levy S., Fayez I., Taguchi N., Han J.-Y., Aiello J., Matsui D., et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone. 2009; 44(3): 428-30. doi: 10.1155/2011/520516
  17. Vera L., Oddo S., DiIorgi N., Bentivoglio G., Giusti M. Primary hyperparathyroidism in pregnancy treated with cinacalcet: a case report and review of the literature. J. Med Case Reports. 2016; 10(1): 361. doi: 10.1186/s13256-016-1093-2
  18. Horjus C., Groot I., Telting D., van Setten P., van Sorge A., Kovacs C.S., et al. Cinacalcet for hyperparathyroidism in pregnancy and puerperium. J. Pediatr Endocrinol Metab. 2009; 22(8):741-9.
  19. Nadarasa K., Bailey M., Chahal H., Raja O., Bhat R., Gayle C., et al. The use of cinacalcet in pregnancy to treat a complex case of parathyroid carcinoma. Endocrinol Diabetes Metab Case Rep. 2014:140056. doi: 10.1530/EDM-140056
  20. Дедов И.И., Мельниченко Г.А., Мокрышева Н.Г., Рожинская Л.Я., Кузнецов Н.С., Пигарова Е.А., Еремкина А.К., Егшатян Л.В., Мамедова Е.О., Крупинова Ю.А. Первичный гиперпаратиреоз: клиника, диагностика, дифференциальная диагностика, методы лечения Проблемы эндокринологии. 2016; 62 (6): 40-77. DOI: 10.14341/ probl201662640-77
  21. Мельниченко Г.А., Дзеранова Л.К., Пигарова Е.А., Воротникова С.Ю., Рожинская Л.Я., Дедов И.И. Федеральные клинические рекомендации по гиперпролактинемии: клиника, диагностика, дифференциальная диагностика и методы лечения. Проблемы эндокринологии. 2013; 59 (6):19-26.
  22. Дедов И.И., Молитвослова Н.Н., Рожинская Л.Я., Мельниченко Г.А. Федеральные клинические рекомендации по клинике, диагностике, дифференциальной диагностике и методам лечения акромегалии. 2013; 59(6): 4-18.
  23. Laway B.A. Pregnancy in acromegaly. Ther Adv Endocrinol Metab. 2015; 6(6): 267-72. doi: 10.1177/2042018815603927
  24. Lima A.D., Alves V.R., Rocha A.R., Martinhago A.C., Martinhago C., Donadio N., et al. Preimplantation genetic diagnosis for a patient with multiple endocrine neoplasia type 1: case report. JBRA Assist Reprod. 2018.; 22(1): 67-70. doi: 10.5935/1518-0557.20180010

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies